ARTICLE | Clinical News

Tegobuvir: Additional Phase IIa data

April 11, 2011 7:00 AM UTC

Additional data from the open-label, international Phase IIa Study 196-0112 trial in 42 treatment-naïve patients with HCV genotype 1 infection showed that dual therapy with twice-daily 40 mg tegobuvir and twice-daily 75 mg GS 9256 (n=15) produced an RVR rate defined as HCV RNA levels <=25 IU/mL at day 28 of 7%. Triple therapy with tegobuvir, GS 9256 and Copegus ribavirin (n=13) and quad therapy with tegobuvir, GS 9256, Copegus and Pegasys peginterferon alfa-2a (n=14) produced RVR rates of 38% and 100%, respectively. Additionally, 80%, 100% and 100% of patients receiving Pegasys and Copegus alone after the 28-day treatment period from the dual, triple and quad therapy arms, respectively, achieved a complete early virologic response (cEVR) defined as HCV RNA levels <25 IU/mL at week 12. Data were presented at the European Association for the Study of the Liver meeting in Berlin. ...